AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15627208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm cranking and leg cycling at 20% of VO(2peak) (AC(60)LC(20))
Number of subjects: 8
Study 15627208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm cranking and leg cycling at 40% of VO(2peak) (AC(60)LC(40))
Number of subjects: 8
Study 12380919 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar plus bipolar recordings
Number of subjects: 44
Study 12380919 — intervention group
Group type: COMPARATOR
Intervention: Bipolar recordings
Number of subjects: 44
Study 9637189 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(‐1))
Number of subjects: 9
Study 9637189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7865932 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped behavioral treatment program
Number of subjects: 66
Study 7865932 — intervention group
Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 66
Study 7865932 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 66
Study 2492748 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of penicillin V once daily for ten days
Number of subjects: 154
Study 2492748 — intervention group
Group type: COMPARATOR
Intervention: 250 mg of penicillin V three times daily for ten days
Number of subjects: 154
Study 1058303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% iodine mouthwash
Number of subjects: 36
Study 1058303 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of iodine solution (2.0% I2 and 2.4% NaI) with brushing and flossing
Number of subjects: 36
Study 1058303 — intervention group
Group type: COMPARATOR
Intervention: Brushing and flossing only
Number of subjects: 36
Study 1058303 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of iodine solution only
Number of subjects: 36
Study 1058303 — intervention group
Group type: COMPARATOR
Intervention: Topical application of distilled water only
Number of subjects: 36
Study 11235558 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (10 mg/kg.day for 5 days)
Number of subjects: 0
Study 31342470 — intervention group
Group type: EXPERIMENTAL
Intervention: Gist condition responses
Number of subjects: 0
Study 31342470 — intervention group
Group type: COMPARATOR
Intervention: High-GIS versions
Number of subjects: 0
Study 31342470 — intervention group
Group type: COMPARATOR
Intervention: Discussion sections of psychology journal articles
Number of subjects: 0
Study 31342470 — intervention group
Group type: COMPARATOR
Intervention: News reports
Number of subjects: 0
Study 29995761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of local anesthetics (lidocaine and bupivacaine) and steroid (methylprednisolone)
Number of subjects: 36
Study 29995761 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IPB group)
Number of subjects: 36
Study 29995761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of local anesthetics and steroids (MLB group)
Number of subjects: 36
Study 27296978 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTAS intervention for drug users with a treatment history
Number of subjects: 295
Study 27296978 — intervention group
Group type: COMPARATOR
Intervention: ARTAS intervention for drug users without a treatment history
Number of subjects: 295
Study 24893214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein
Number of subjects: 48
Study 24893214 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg-white protein
Number of subjects: 48
Study 24893214 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 48
Study 24893214 — intervention group
Group type: COMPARATOR
Intervention: Milk protein
Number of subjects: 48
Study 24893214 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 48
Study 24893214 — intervention group
Group type: COMPARATOR
Intervention: Protein mix
Number of subjects: 48
Study 22586483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2500 IU daily for 4 months
Number of subjects: 114
Study 22586483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 22586483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2500 IU
Number of subjects: 114
Study 20828221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 35
Study 20828221 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 35
Study 17420604 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing 3.0 or 4.0 g of KM‐CW/d for 8 weeks
Number of subjects: 0
Study 17420604 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 0
Study 17420604 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing 3.0 or 4.0 g of KM‐CW/d
Number of subjects: 0
Study 15793437 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 30
Study 15793437 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 30
Study 12027255 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser scaling
Number of subjects: 40
Study 12027255 — intervention group
Group type: COMPARATOR
Intervention: Conventional scaling and root planing or ultrasonic instruments
Number of subjects: 40
Study 10622037 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV + AZT + 3TC
Number of subjects: 0
Study 10622037 — intervention group
Group type: COMPARATOR
Intervention: IDV + AZT + 3TC
Number of subjects: 0
Study 10622037 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV + IDV
Number of subjects: 0
Study 7861019 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (nucleoside reverse transcriptase inhibitor)
Number of subjects: 0
Study 7861019 — intervention group
Group type: COMPARATOR
Intervention: Prior zidovudine therapy
Number of subjects: 0
Study 1682356 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol combined with H2RA
Number of subjects: 0
Study 1682356 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-1749 (proton-pump inhibitor)
Number of subjects: 0
Study 1682356 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists (H2RAs)
Number of subjects: 0
Study 7011526 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern low-dose mammography screening
Number of subjects: 0
Study 7011526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 31972587 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin (Actrapid) 10 units (0.1 mL) in 1 mL of normal saline, applied twice daily.
Number of subjects: 42
Study 31972587 — intervention group
Group type: COMPARATOR
Intervention: Topical normal saline (placebo).
Number of subjects: 42
Study 29726627 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported swelling (any swelling vs none)
Number of subjects: 276
Study 29726627 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported constant swelling (versus none or intermittent)
Number of subjects: 276
Study 28624041 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing saline solution during surgery (experimental group)
Number of subjects: 52
Study 28624041 — intervention group
Group type: COMPARATOR
Intervention: Normal saline not replaced during surgery (control group)
Number of subjects: 52
Study 25714536 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Group (Eye Retinopathy Trainer®)
Number of subjects: 90
Study 25714536 — intervention group
Group type: COMPARATOR
Intervention: Control Group (traditional method)
Number of subjects: 90
Study 24700991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 - breastfeeding deferred for at least 1 hour before and after each dose of rotavirus vaccine
Number of subjects: 204
Study 24700991 — intervention group
Group type: COMPARATOR
Intervention: Group 2 - unrestricted breastfeeding encouraged
Number of subjects: 204
Study 22863242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet-based regimen
Number of subjects: 552
Study 22863242 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 552
Study 22863242 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved iPTH ≤ 300 pg/mL
Number of subjects: 552
Study 22863242 — intervention group
Group type: EXPERIMENTAL
Intervention: Did not achieve iPTH ≤ 300 pg/mL
Number of subjects: 552
Study 19085634 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g daily)
Number of subjects: 91
Study 19085634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 17726611 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg in 1 ml subcutaneously twice a week for 2 weeks)
Number of subjects: 12
Study 17726611 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 12
Study 14978006 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 16
Study 14978006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12166713 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% triclosan and essential oil
Number of subjects: 120
Study 12166713 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 120
Study 12166713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 9534101 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-trandolapril
Number of subjects: 100
Study 9534101 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 100
Study 7713812 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in the morning (1130)
Number of subjects: 20
Study 7713812 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in the afternoon (1630)
Number of subjects: 20
Study 7713812 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in December (darkness period)
Number of subjects: 20
Study 7713812 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in April (18 h of daylight)
Number of subjects: 20
Study 7713812 — intervention group
Group type: EXPERIMENTAL
Intervention: Females during exercise
Number of subjects: 20
Study 7713812 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of variance for sex, time of exercise, and season
Number of subjects: 20
Study 2569993 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/day azelastine once daily
Number of subjects: 111
Study 2569993 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/day azelastine twice daily
Number of subjects: 111
Study 2569993 — intervention group
Group type: COMPARATOR
Intervention: 1 mg ketotifen twice daily
Number of subjects: 111
Study 863837 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ascorbic acid
Number of subjects: 13
Study 863837 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid
Number of subjects: 13
Study 863837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30401528 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2127
Study 30401528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 30401528 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (low European System for Cardiac Operative Risk Evaluation score)
Number of subjects: 2127
Study 27351896 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM‐500 (500 ms stimulus duration; n=28)
Number of subjects: 81
Study 27351896 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM‐1250 (1250 ms stimulus duration; n=26)
Number of subjects: 81
Study 27351896 — intervention group
Group type: COMPARATOR
Intervention: ABM‐Placebo (sham training; n=27)
Number of subjects: 81
Study 26316026 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHGE) at 50% of maximal voluntary contraction (8 min/day)
Number of subjects: 30
Study 26316026 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 ml/day of concentrated beetroot juice
Number of subjects: 30
Study 26316026 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 30
Study 24150234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 1088
Study 24150234 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1088
Study 21276218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise commercials
Number of subjects: 125
Study 21276218 — intervention group
Group type: COMPARATOR
Intervention: Control commercials (neutral products)
Number of subjects: 125
Study 19813461 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ramipril (10 mg)
Number of subjects: 40
Study 19813461 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of ramipril (10 mg)
Number of subjects: 40
Study 17725471 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing strengthening program
Number of subjects: 88
Study 17725471 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing strengthening program
Number of subjects: 88
Study 15213206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/d
Number of subjects: 7479
Study 15213206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate (MPA) 0.625 mg/d + 2.5 mg/d
Number of subjects: 7479
Study 15213206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from estrogen-alone and estrogen plus progestin trials
Number of subjects: 7479
Study 15213206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined trial data
Number of subjects: 7479
Study 11779390 — intervention group
Group type: EXPERIMENTAL
Intervention: zanamivir (Relenza)
Number of subjects: 0
Study 9533558 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation
Number of subjects: 6
Study 9533558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7882462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinfosiltine (S12363) at 0.3 mg/m2 given weekly
Number of subjects: 22
Study 7882462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinfosiltine (S12363) at 0.6 mg/m2 given every 2 weeks
Number of subjects: 22
Study 2204548 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stripping of the long saphenous vein
Number of subjects: 42
Study 2204548 — intervention group
Group type: COMPARATOR
Intervention: High ligation
Number of subjects: 42
Study 2204548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (standard stripping and high ligation)
Number of subjects: 42
Study 2204548 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved saphenous veins
Number of subjects: 42
Study 391623 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 20
Study 391623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 20
Study 391623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid and dipyridamole
Number of subjects: 20
Study 391623 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 31912860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin-enriched foods
Number of subjects: 22
Study 30819510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg single dose
Number of subjects: 20
Study 30819510 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 20
Study 30819510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 20
Study 28693563 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (group A)
Number of subjects: 175
Study 28693563 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (group E)
Number of subjects: 175
Study 28693563 — intervention group
Group type: COMPARATOR
Intervention: Shallow‐puncture (group B)
Number of subjects: 175
Study 28693563 — intervention group
Group type: COMPARATOR
Intervention: Non‐acupoint acupuncture (group C)
Number of subjects: 175
Study 28693563 — intervention group
Group type: COMPARATOR
Intervention: Non‐acupoint shallow‐puncture (group D)
Number of subjects: 175
Study 25708763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 139
Study 25708763 — intervention group
Group type: COMPARATOR
Intervention: Cold forceps polypectomy (CFP)
Number of subjects: 139
Study 23910795 — intervention group
Group type: EXPERIMENTAL
Intervention: AT Basel mutation (p.Pro73Leu)
Number of subjects: 104
Study 23910795 — intervention group
Group type: EXPERIMENTAL
Intervention: AT activity assays
Number of subjects: 104
Study 23910795 — intervention group
Group type: EXPERIMENTAL
Intervention: No mutation detected
Number of subjects: 104
Study 20093975 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Group (HRG)
Number of subjects: 27
Study 20093975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptive Group (PG)
Number of subjects: 27
Study 20093975 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 27
Study 18445072 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent reported in trial protocols
Number of subjects: 312
Study 18445072 — intervention group
Group type: COMPARATOR
Intervention: Active controls
Number of subjects: 312
Study 18445072 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trial provisions
Number of subjects: 312
Study 18445072 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate outcomes
Number of subjects: 312
Study 18445072 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-important outcomes
Number of subjects: 312
Study 18445072 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcomes in low income countries
Number of subjects: 312
Study 18445072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical company involvement
Number of subjects: 312
Study 17276855 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (intraosseous screw without acrylic plate)
Number of subjects: 40
Study 17276855 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (intraosseous screw with acrylic plate resembling Nance button)
Number of subjects: 40
Study 15483465 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)/Ritonavir (RTV) at 800/200 mg (arm A)
Number of subjects: 44
Study 15483465 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (IDV)/Ritonavir (RTV) at 400/400 mg (arm B)
Number of subjects: 44
Study 11237912 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year diabetes educational intervention arm (mailed packets and newsletters focused on vision care)
Number of subjects: 2308
Study 11237912 — intervention group
Group type: COMPARATOR
Intervention: Control nonintervention arm
Number of subjects: 2308
Study 11600092 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg (single annual dose)
Number of subjects: 0
Study 9315596 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil plus simvastatin
Number of subjects: 0
Study 9315596 — intervention group
Group type: COMPARATOR
Intervention: Marine oil
Number of subjects: 0
Study 9315596 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study 8101554 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of left internal thoracic arteries (LITAs)
Number of subjects: 25
Study 8101554 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of right internal thoracic arteries (RITAs)
Number of subjects: 25
Study 8101554 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-dilated ITAs)
Number of subjects: 25
Study 8101554 — intervention group
Group type: COMPARATOR
Intervention: Papaverine injection
Number of subjects: 25
Study 3550455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (0.75-1 mg/kg/day for the first 6 months and 1.5-2 mg/kg/day for the next 12 months)
Number of subjects: 105
Study 3550455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 3550455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 105
Study 3550455 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine and Placebo
Number of subjects: 105
Study 2515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 16
Study 2515880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 16
Study 2515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measurements of S‐TK and neutrophil counts
Number of subjects: 16
Study 31107775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive behavioral intervention (five monthly in-home sessions and telephone consultations)
Number of subjects: 112
Study 31107775 — intervention group
Group type: COMPARATOR
Intervention: General conversations with nurse interventionists (control group)
Number of subjects: 112
Study 28734822 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib 125 mg orally (three times per day)
Number of subjects: 176
Study 28734822 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain irradiation (WBI) 30 Gy in ten fractions of 3 Gy plus chemotherapy for 4-6 cycles
Number of subjects: 176
Study 26370656 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE500 (500 mg)
Number of subjects: 20
Study 26370656 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1500 (1500 mg)
Number of subjects: 20
Study 26370656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23351824 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA 1 g/daily
Number of subjects: 1203
Study 23351824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1203
Study 21283919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil UVA/UVB Defense SPF 50 sunscreen exposed to natural sunlight (4 doses ranging from 2–6 MED)
Number of subjects: 0
Study 21283919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil UVA/UVB Defense SPF 50 sunscreen unexposed to sunlight
Number of subjects: 0
Study 21283919 — intervention group
Group type: COMPARATOR
Intervention: UVB-SPF 15 control sunscreen
Number of subjects: 0
Study 19453893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 0
Study 19453893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 0